Sabin Vaccine Institute 2012 Annual Report

20 Years of Advancing Smart Solutions for Vaccine-Preventable and Neglected Tropical Diseases

Annual Report 2012

For 20 years, the Sabin Vaccine Institute has invested in

advancing smart solutions to vaccine-

preventable and neglected tropical diseases.

Extremely low-cost interventions strengthen

communities and boost economies.

Through research and advocacy, we advance

public health initiatives that are not only

cost-effective, but sustainable for the

long term. We invite you to join us in our

continuing efforts over the next 20 years.

3 Letter from the Chairman, CEO and President

4 A History of Smart Investments in Health

8 Fostering a Decade of Vaccines

12 Unprecedented Research and Development

16 Creating a Movement

20 Snapshot of Key Moments

26 Expanding in Europe

28 Board of Trustees and Senior Leadership

29 Awards and Recognition

30 Financial Report

32 Thank You

Table of Contents

1

2

We are pleased to present the Sabin Vaccine Institute

(Sabin) 2012 annual report. The past year marked the

20th year of Sabin’s operations, which have included

groundbreaking programs in vaccine development and

advocacy projects helping the world’s poor gain access

to much-needed vaccines and medicine.

Our performance over the past two decades is a

testament to the spirit of innovation, partnership and

strategic leadership that Sabin has brought to the

global health community. Through this work, we are

uniquely positioned to deliver on the promise of a

healthier future for billions of people.

During the past year, we advanced the effort to achieve

universal access to vaccines. Our Vaccine Advocacy

and Education program, led by Dr. Ciro de Quadros,

launched the International Association of Immunization

Managers, the first global professional association

for immunization program managers. We became a

core partner in the new ProVac International Working

Group, which is expanding an innovative model to

help countries decide when to introduce new vaccines.

Our Sustainable Immunization Financing program grew

to 18 pilot countries, scaling up our efforts to strengthen

national sources of funding for immunization programs.

In addition, we spearheaded advocacy initiatives to

reduce the burden of typhoid and paratyphoid fevers,

dengue fever, meningococcal disease, pneumococcal

disease, rotavirus, and rubella and congenital rubella

syndrome, among others.

Under the leadership of Dr. Peter Hotez, the Sabin

Vaccine Institute Product Development Partnership

(Sabin PDP) is at the forefront of developing and

testing new vaccines to prevent neglected tropical

diseases (NTDs). In 2012, our human hookworm

vaccine candidate, Na-GST-1, entered clinical trials

Letter from the Chairman, CEO and President

in the United States; concurrently, in an ongoing

clinical trial in Brazil, no safety issues were observed

when healthy adults who had not been exposed

to hookworm received the vaccine. We began a

toxicology study for our schistosomiasis vaccine

candidate, in preparation for filing an investigational

new drug application in 2013. Additionally, we

expanded our portfolio with new vaccine projects

focused on Chagas disease, leishmaniasis and severe

acute respiratory syndrome (SARS).

The Global Network for Neglected Tropical Diseases,

headed by Dr. Neeraj Mistry, also had a pivotal year

as we worked with our international partners to

expand and strengthen NTD control programs. In 2012,

we mobilized funding to deliver life-changing NTD

treatments to more than 90 million people. With support

from philanthropist Dr. Gary Michelson, we announced

the appointment of four new NTD Special Envoys who

raise the visibility of the effects of debilitating NTDs

among heads of state and senior government officials.

Furthermore, we launched an exciting new advocacy

campaign called END7, which works in partnership with

celebrities and entertainment and media companies to

promote the NTD cause to millions of people.

Our work over the past 20 years has reinforced our

conviction that good health is essential to enabling

communities to break free from poverty. As we face

the challenges and opportunities of the next decade,

we look forward to continuing our collaboration with

partners and supporters from around the world. We thank

you for your commitment to Sabin Vaccine Institute’s

vision of healthy, prosperous communities everywhere.

Morton P. Hyman

Chairman

Michael W. Marine,

Ambassador (Ret.)

CEO

Peter J. Hotez,

M.D., Ph.D.

President

3

A History of Smart Investments

in Health TO IMPROVE THE LIVES OF BILLIONS

20 Years at Work

Translating Our Mission into Action

At Sabin, we focus on reducing needless human suffering from vaccine-

preventable and neglected tropical diseases by developing new vaccines,

advocating for increased use of existing vaccines and promoting expanded

access to affordable medical treatments.

Since the start of our Human Hookworm Vaccine Initiative in 2000, Sabin has

become a leader in the world of non-profit vaccine product development.

Today, the Sabin Vaccine Institute Product Development Partnership unites

a group of experienced research institutions, national and international

manufacturers and other partners to advance a portfolio of five vaccine

projects, with more to come in 2013.

In 2012, our staff published more than 25 peer-reviewed and scientific

journal articles in outlets that include the Lancet, Vaccine, British Medical

Journal, Journal of Allergy and Clinical Immunology, PLOS Neglected

Tropical Diseases and many others.

We specialize in advocacy. We engage global leaders and public institutions

by convening coalitions, hosting training sessions and conferences, and

conducting new research to ensure that decision-makers have the best-

available information on vaccine-preventable diseases.

5

20 Years at Work

We have successfully increased the visibility of seven NTDs that infect more

than 1 billion people around the world. One of our initiatives – the Global

Network for Neglected Tropical Diseases – has played an indispensible role

in leading global advocacy for the control and elimination of the most

common of these diseases, that have plagued the world's poor since biblical

times. The fight against these diseases – which can be treated for

approximately 50 cents per person per year – is gaining increased global

political and public support each year.

A Brighter Future

We are confident in our ability to achieve ambitious health goals. By the

year 2020, we anticipate contributing to the next major milestones in

public health, including controlling or eliminating up to 10 NTDs as public

health threats; developing new vaccines that will free more than 1 billion

people from the threat of NTDs and other infectious diseases; and

exceeding Millennium Development Goal 4 by reducing child deaths by

two-thirds compared to 1990 through expanding access to new and

underutilized vaccines.

50 ¢

6

Major Funding Commitments Supporting Sabin Programs Over the past five years, we have secured grant commitments totaling more than US $120 million. Some of our most significant grants are listed below.

20 Years at Work

THE SABIN PDP

received US $6 million+ in grants in 2012 while continuing to seek additional funding for ongoing research and development activities. Major grants over the past five years include:

US $12.1 MILLION

over four years from the Bill

& Melinda Gates Foundation

to support our human

hookworm vaccine

€ 5.9 MILLION

over four years from the Dutch

Ministry of Foreign Affairs to

support the development of the

human hookworm vaccine

US $1.3 MILLION

in philanthropic funding to support

our schistosomiasis vaccine from

Mort and Chris Hyman, the

Blavatnik Family Foundation and

Dr. Gary Michelson

THE GLOBAL NETWORK FOR

NEGLECTED TROPICAL DISEASES

received US $40 million in grants since 2008 to conduct advocacy and resource mobilization efforts that leveraged US $114 million in resources for NTD treatment programs. Major grants over the past five years include:

US $37.6 MILLION

over five years from the Bill

& Melinda Gates Foundation to

mobilize resources and conduct

strategic advocacy work for NTD

treatment programs

US $1 MILLION

over four years from the Hoffman

Family Foundation in support of

NTD treatment programs

VACCINE ADVOCACY

AND EDUCATION

received US $9 million+ in grants for 18 individual programs and events to advocate for immunization in 2012. Major grants over the past five years include:

US $9.2 MILLION

over five years from the Bill &

Melinda Gates Foundation

to support the Sustainable

Immunization Financing program

US $4.9 MILLION

over five years from the Bill &

Melinda Gates Foundation to

support the International

Association of Immunization

Managers

US $3.7 MILLION

over three years from the Bill

& Melinda Gates Foundation to

support the Coalition against

Typhoid Secretariat

US $2 MILLION

over three years from sanofi

pasteur to support advocacy

related to the pertussis vaccine

7

Fostering a Decade of Vaccines

TO EXTEND THE BENEFITS OF IMMUNIZATION TO ALL

“ We must prioritize the critical health issues of the young, the old and everyone in between in the public health agenda, so that no one suffers from vaccine-preventable diseases.”

Dr. Ciro de Quadros

Vaccine Advocacy and Education

Vaccines are some of the most valuable public health tools available today.

However, challenges still remain in our work to ensure that people – no

matter who they are or where they are born – have full access to all life-

saving vaccines.

In the last year, Sabin played a critical role in the development of a new

roadmap for making vaccines accessible to everyone by 2020. Sabin

Executive Vice President Dr. Ciro de Quadros served as a co-chair of the

Steering Committee for the Decade of Vaccines Collaboration, which led

the development of the Global Vaccine Action Plan that was unanimously

endorsed by the World Health Assembly in May 2012.

Enhancing Decision-Making and Strengthening Country Ownership

We expanded our vaccine advocacy

operations with the start of two

new initiatives focused on educating

stakeholders and decision-makers.

We launched the International

Association of Immunization

Managers (IAIM), the first global

professional association for

immunization program managers

– those who manage the

day-to-day operations of national

immunization programs.

Through our leadership in the new

ProVac International Working Group

– first developed and tested by the

Pan American Health Organization

(PAHO) – Sabin is helping countries

to conduct economic analyses

prior to deciding to introduce

new vaccines.

Sabin’s long-standing Sustainable

Immunization Financing (SIF) program

demonstrated measurable progress in

increasing country-level commitment

to immunization, as the number of

countries involved in this pilot effort

grew to 18, and the SIF team facilitated

more than 90 advocacy events, inclu-

ding national briefings, meetings and

peer exchanges throughout the year.

9

Lending Our Voices to Disease Prevention Efforts

Preventable diseases like meningitis, typhoid and paratyphoid fevers,

rotavirus, dengue fever, pneumonia, rubella and congenital rubella

syndrome, pertussis and human papilloma virus (HPV) take the lives of

nearly 2 million people every year. Sabin addresses the clear need for

increased global action to prevent these diseases through targeted

advocacy, education and training.


ERADICATE MEASLES AND

RUBELLA IN EVERY REGION

In 2012, Sabin partnered with the

International Pediatric Association

in a joint effort to eradicate measles

and rubella in every region by 2020.

PATHWAY FOR NEXT

GENERATION TYPHOID VACCINES

Serving as the Secretariat of the

Coalition against Typhoid (CaT),

Sabin began work with the World

Health Organization (WHO) to define

the regulatory pathway for next

generation typhoid vaccines and

convened experts in mathematical

modeling to review state-of-the-art

typhoid transmission models.

ADDRESS DENGUE

Through our work in the Dengue

Vaccine Initiative, we increased

public awareness and political will

to address this mosquito-borne

disease, which threatens 40 percent

of the world’s population.

Additionally, in 2012 Sabin organized conferences, trainings and educational

sessions, attracting hundreds of high-level decision-makers representing

government, academia, civil society and the media. Together with PAHO,

we hosted the First Regional Meningococcal Symposium in Latin America,

which shared preliminary data from a Sabin-led study on the burden and

costs of meningococcal disease in the region, estimated at US $50-60

million annually. We also convened more than 300 stakeholders at the 10th

International Rotavirus Symposium in Thailand.

10


24-26 millionestimated future deaths could be averted by meeting the immunization goals of the Global Vaccine Action Plan

$9 million+ in grants received for 18 individual programs and events to advocate for immunization in 2012

Launched the first global professional association for immunization program managers

100+stakeholder meetings, conferences and trainings convened in 2012

18 pilot countries included in the expanded Sustainable Immunization Financing program

11

Unprecedented Research and

DevelopmentTO PREVENT DISEASE, REDUCE ILLNESS AND BOLSTER ECONOMIES

“ We are filling a gap to produce vaccines for the world’s poorest people, where no traditional commercial market exists.”

Dr. Peter Hotez

The Sabin Vaccine Institute Product Development Partnership

In 2012, the Sabin Vaccine Institute Product Development Partnership

(Sabin PDP) accelerated efforts to develop and test new vaccines. We expect

significant progress over the next five years as we prepare to transition

several vaccine candidates into clinical trials and continue ongoing trials for

our human hookworm vaccine.

HOOKWORM VACCINE

CLINICAL TRIALS ADVANCE

The ongoing Phase 1 clinical trial

of our hookworm vaccine candidate

Na-GST-1 moved to Part II after

an independent Safety Monitoring

Committee determined that the

vaccine candidate resulted in no

safety issues for healthy adults

who had never been exposed to

hookworm. Subsequently, hook-

worm-exposed adults started

receiving the vaccine candidate.

We commenced a second Phase 1

clinical trial for healthy adults of

Na-GST-1 at Children’s National

Medical Center in Washington,

D.C. In addition, we submitted an

investigational new drug (IND)

application to the U.S. Food and

Drug Administration for our second

hookworm vaccine candidate,

Na-APR-1, a necessary step prior to

conducting clinical testing, which is

expected to begin in 2013.

NEW CUTANEOUS LEISHMANIASIS

VACCINE STRATEGIES

Since 2011, the Sabin PDP has been

working to identify new strategies

for the development of a vaccine to

prevent cutaneous leishmaniasis, the

most common form of leishmaniasis,

which is transmitted by the bite of a

sand fly and infects as many as 1.2

million people each year.

13

BUILDING MOMENTUM IN

SCHISTOSOMIASIS

VACCINE DEVELOPMENT

Schistosomiasis is one of the

world's most damaging and deadly

parasitic infections. The intestinal

form infects more than 80 million

people, causing anemia and

hemorrhaging. Female genital

schistosomiasis is the most

common gynecologic condition

in Africa, affecting as many as 120

million girls and young women,

A NEW THERAPEUTIC

VACCINE FOR CHAGAS DISEASE

Chagas disease is a leading cause

of heart disease, affecting

approximately 10 million people,

primarily in Latin America. The only

drugs available to treat Chagas

disease today have limitations –

treatment courses are often costly

and lengthy and may not always

be effective. A therapeutic Chagas

and is linked to a multifold increase

in acquiring HIV/AIDS.

Our intestinal schistosomiasis

vaccine candidate, Sm-TSP-2,

began a Good Laboratory Practices

toxicology study in 2012 – an

important step that will determine

preclinical safety of the vaccine

candidate and enable submission of

an IND application to the U.S. Food

and Drug Administration in 2013,

to be followed by the start of Phase

1 clinical testing.

disease vaccine could prevent more

than 10,000 deaths from the disease

each year.

With support from the Carlos Slim

Institute for Health, the Southwest

Electronic Energy Medical Research

Institute, Texas Children’s Hospital

and other academic and industrial

partners, the Sabin PDP is in the

early preclinical stages of developing

a new therapeutic vaccine targeting

Chagas disease.

STRENGTHENING BIODEFENSE

WITH A SARS VACCINE

Severe acute respiratory syndrome

(SARS) emerged as a global cause

for concern when it produced more

than 8,000 infections and approxi-

mately 800 deaths in China from

2002-2003. A SARS vaccine could

protect vulnerable populations such


as the elderly and health care and

laboratory personnel in the face of

future outbreaks.

The Sabin PDP – together with

partners in industry, academia and

the military – is working to develop

and manufacture a SARS vaccine

within the next five years.

14


Vaccines in development

to address 5 diseases

New vaccines will tackle diseases that infect 1 billion+ people

Hookwormvaccine candidate progressing in two Phase 1 clinical trials

Schistosomiasis vaccine candidate prepared for IND submission

$6 million+ in grants received in 2012. We continue to seek additional funding for ongoing research and development activities

15

Creating a

MovementTO CONTROL AND ELIMINATE KEY NEGLECTED

TROPICAL DISEASES THIS DECADE

“ Drug donations from pharmaceutical companies are just the beginning of a comprehensive collaboration between the private sector, NGOs and country governments that will help us to meet our 2020 control and elimination targets for neglected tropical diseases.”

Dr. Neeraj Mistry

Global Network for Neglected Tropical Diseases

Since 2006, the Global Network for Neglected Tropical Diseases (Global

Network) has led the charge in raising the awareness, political will and

resources necessary to eliminate and control the seven most common

neglected tropical diseases (NTDs): hookworm, whipworm, roundworm,

lymphatic filariais (elephantiasis), schistosomiasis (bilharzia), onchocerciasis

(river blindness) and trachoma.

In early 2012, under the leadership of the Bill & Melinda Gates Foundation,

WHO, World Bank and others, the global community came together in an

unprecedented way to sign the London Declaration on NTDs, a commitment

to control and eliminate 10 NTDs by 2020. As a signatory of the London

Declaration, the Global Network is working to meet the ambitious but

achievable challenges set for this decade.

Catalyzing New Funding

Fifty cents can be incredibly

powerful. It’s the annual cost to treat

and protect an individual from the

seven most common NTDs. In 2012,

we mobilized enough new funding

to treat more than 90 million people

against NTDs through programs in

endemic countries, and, since 2008,

we mobilized sufficient funding to

treat more than 300 million people.

NTDs on the Global Agenda

We cultivated strong support for

NTD programs in the United

States and abroad. We briefed

more than 250 members of the

U.S. Congress about NTDs through

policy briefings, visits and targeted

outreach throughout the year.

U.S. government funding for NTD

programs increased from US $15

million in fiscal year (FY) 2006 –

the first year of funding – to US $89

million in FY 2012. The United

Kingdom announced a five-fold

increase to its commitment to NTD

programs in early 2012 to £245

million over four years – evidence

that NTD treatment is a well-

recognized, vital and cost-effective

way to improve lives around

the world.

50 ¢

17

In addition, we significantly expanded

our efforts to engage governments

beyond the United States and

United Kingdom in support of cost-

effective NTD programs through

15 international high-level advocacy

trips to meet with senior government

officials in parliament, bilateral aid

agencies, presidential offices, and

ministries of health and foreign affairs.

Strengthening Regional Institutions

With partners at WHO regional

offices, regional development banks,

non-governmental organizations and

country governments, we helped to

create and advance sustainable NTD

policies and programs in the three

regions where the burden is the

highest: Africa; Asia and the Pacific;

and Latin America and the Caribbean.

By the end of 2012, nearly 60

countries had national integrated

plans of action for NTD control. In

Africa, three countries – Burundi,

Cameroon and Mozambique –

launched their national NTD plans

in 2012. In Latin America and the

Caribbean, Honduras and Brazil

became the first countries to launch

their national integrated NTD plans,

while 11 other countries in the

region made progress in developing

draft plans. Meanwhile, in Asia, the

Western Pacific and South-East Asia

regions both launched NTD Regional

Strategic Action Plans.


Winning over the Public

We launched the END7 campaign in

January 2012 to engage the general

public in the work to control and

eliminate NTDs.

The campaign achieved important

metrics of success in its first year

by recruiting more than 30 actors,

musicians and other influential

members of the entertainment

industry to participate in a Twitter

“Day of Action” that reached more

than 50 million people with

important information on NTDs.

18


In its first year, the END7 campaign reached

50 million+ people

US and UK governments made increased commitments to NTD programs of US $89 million and £245 million, in 2012

60 countries have national, integrated plans to address NTDs

$40 millionin grants received since 2008 to conduct advocacy and resource mobilization efforts that leveraged US $114 million in resources for NTD treatment programs

Since 2008, mobilized funding to support

treatment of 300 million+ people

19

Snapshot of Key Moments

CATALYTIC EVENTS FROM 2012

20

PROGRESS TOWARD RUBELLA

ELIMINATION AND CRS

PREVENTION IN EUROPE

Rome, Italy

Sabin, together with the March of

Dimes Foundation, the World Health

Organization Regional Office for

Europe, the International Pediatric

Association and its regional affiliate,

the European Pediatric Association

and the U.S. Centers for Disease

Control and Prevention (CDC),

convened more than 150 people

from 47 countries to review the

latest developments in the fight

against rubella and congenital

rubella syndrome in Europe.

FIRST REGIONAL

MENINGOCOCCAL SYMPOSIUM

Buenos Aires, Argentina Sabin and the Pan American Health

Organization (PAHO) convened a

symposium to reveal preliminary

results from the first-ever study

to estimate the burden and costs

of meningococcal disease in

Latin America. Preliminary data

suggested at least 10,000 cases

of meningococcal disease occur

each year, costing the region US

$50-60 million in hospitalizations,

opportunity costs and long-term

disability.

THE CALL TO FIGHT NTDS Washington, D.C., USAThe Center for Strategic and

International Studies and the Global

Network called together key leaders

in Washington, D.C. to highlight

emerging African leadership and

philanthropy in the fight against

NTDs, particularly the leadership of

Nigerian General T.Y. Danjuma, the

London Declaration and multi-

sectoral partnerships, such as the

World Bank’s African Programme

for Onchocerciaisis Control.

NEW NTD SPECIAL ENVOYS ANNOUNCED

Washington, D.C., USA His Excellency John A. Kufuor

(President of the Republic of

Ghana, 2001-2009), His Excellency,

President Alvaro Arzú Irigoyen

of Guatemala (1996-2000),

His Excellency, President Ricardo

Lagos Escobar of Chile (2000-2006)

and former PAHO Director

Dr. Mirta Roses Periago joined Sabin

and the Global Network as NTD

Special Envoys.

2012 at a Glance

21

GLOBAL VACCINE ACTION

PLAN ENDORSED BY WORLD

HEALTH ASSEMBLY

Geneva, Switzerland In May 2012, the 65th World Health

Assembly endorsed the landmark

Global Vaccine Action Plan (GVAP),

a roadmap to prevent millions of

deaths by 2020 through more

equitable access to new and existing

vaccines. The GVAP was coordinated

by the Decade of Vaccines (DoV)

Collaboration, a group of

international vaccine experts

representing leading global health

organizations. Sabin Executive

Vice President Dr. Ciro de Quadros

served as co-chair of the DoV

Steering Committee.

THE 15TH INTERNATIONAL

CONGRESS ON INFECTIOUS

DISEASES Bangkok, Thailand The Sabin-led Coalition against

Typhoid (CaT) Secretariat convened

breakout sessions during the

15th International Congress on

Infectious Diseases to discuss the

high burden of endemic typhoid

in South and Southeast Asia and

the Pacific Islands.

NEW CLINICAL TRIAL OF HUMAN

HOOKWORM VACCINE BEGINS Washington, D.C., USA

The Sabin PDP, in partnership with

The George Washington University

and the Children’s National

Medical Center, began vaccinating

participants in a Phase 1 clinical trial

of Na-GST-1, one of our human

hookworm vaccine candidates.

GLOBAL HEALTH RESEARCH

AND DEVELOPMENT AND THE

HIDDEN BURDEN OF NEGLECTED

TROPICAL DISEASES IN TEXAS

Houston, Texas, USA Sabin partnered with

Research!America, Baylor College of

Medicine’s National School of

Tropical Medicine, Texas Children’s

Hospital and the American Society

of Tropical Medicine and Hygiene to

convene a day-long event with more

than 150 attendees that revealed the

hidden burden of neglected tropical

diseases in Texas.

2012 at a Glance

22

ALLIED TO FIGHT AGAINST

NTDS: CONTRIBUTIONS OF THE

PRIVATE SECTOR

Berlin, GermanyTogether with vfa, an association

of leading research-based

pharmaceutical companies in

Germany, the Global Network led

expert discussions on strategies

for improved collaboration and

increased private sector involvement

in NTD treatment and control

programs. Two separate events

brought together more than 100

individuals representing industry,

civil society, media and academia,

the ambassadors of 10 countries,

and German government officials

and members of Parliament.

SABIN PARTNERS WITH EISAI

FOR VACCINE ANTIGENS

Sabin and Eisai Co., Ltd. announced

a new collaboration to advance

vaccine development efforts. Eisai

provided adjuvant material to enable

the Sabin PDP to expand ongoing

research and development for its

leishmaniasis and Chagas disease

vaccine candidates.

SABIN AND ASEAN FOUNDATION

JOIN TOGETHER AGAINST NTDS Jakarta, Indonesia

Sabin and the Global Network

began to work with ASEAN

Foundation, an inter-governmental

non-profit organization established

by the leaders of the Association

of Southeast Asian Nations, to

encourage greater dialogue and

action on NTD control in the Asia

and Pacific region.

THE 10TH INTERNATIONAL

ROTAVIRUS SYMPOSIUM Bangkok, ThailandSabin, PATH, the Bill & Melinda

Gates Foundation and the CDC

brought together more than 300

stakeholders from 47 countries for

an update on new data and relevant

research to inform public health

agendas related to prevention of

rotavirus gastroenteritis, the most

common cause of diarrheal

hospitalizations and deaths among

children worldwide.

CELEBRATING AN UNTOLD

STORY OF SUCCESS

Washington, D.C., USAThe Global Network jointly

sponsored an event on Capitol Hill

with the U.S. Agency for International

Development and 40 other

non-governmental organizations,

academic institutions, pharmaceutical

companies, and global health and

civil society groups to celebrate

the success of global partnerships

that combat NTDs and announce

the addition of NTDs to the Senate

Working Group on Malaria.

SABIN AND THE INTERNATIONAL

VACCINE INSTITUTE FORM

STRATEGIC ALLIANCE

Seoul, Korea The International Vaccine Institute

and Sabin signed a memorandum

of understanding to form a

strategic alliance around research,

development and advocacy in

support of vaccines and public

health efforts impacting the world’s

poorest populations.

THE 14TH ASIA PACIFIC

CONGRESS OF PEDIATRICS

Kuching, MalaysiaThe CaT Secretariat called together

leading pediatricians from across

Asia to encourage discussion of the

hyper-endemic burden of typhoid

in the region, including antibiotic-

resistant typhoid, and offer solutions

such as vaccine introductions to

combat this growing problem.

2012 at a Glance

23

2012 at a Glance

PLOS NTDS OPEN ACCESS JOURNAL

CELEBRATES FIFTH ANNIVERSARY San Francisco, California, USA The open-access journal, PLOS

NTDs, celebrated its fifth anniversary

by releasing a collection called

“The Geopolitics of NTDs.” Sabin

President Dr. Peter Hotez, who

helped to spearhead the publication,

is currently the co-Editor-in-Chief.

VACCINE INFORMATION SESSION

São Paulo, Brazil In partnership with the Brazilian

Immunization Society, Sabin

arranged a three-day information

session for 22 global health

journalists from nine countries in

the Latin America and Caribbean

region to provide the most recent

information on vaccines and the

process of delivery as background

for public health stories.

SCHISTOSOMIASIS VACCINE CANDIDATE BEGINS TOXICOLOGY

STUDY Chicago, Illinois, USA

A Good Laboratory Practices

toxicology study commenced to

determine the safety, tolerability and

potential toxicity of our intestinal

schistosomiasis vaccine candidate,

Sm-TSP-2, in laboratory animals.

SECOND VACCINOLOGY COURSE

FOR LATIN AMERICA Lima, Peru

Together with the Universidad

Peruana Cayetano Heredia, Sabin

assembled 40 country delegates and

25 expert speakers in vaccinology

to discuss current vaccines and

immunization recommendations,

funding mechanisms and effective

use of communications to help

reduce vaccine-preventable diseases.

COUNTRY IMMUNIZATION

LEGISLATIVE WORKSHOP Kinshasa, Democratic Republic of Congo Sabin’s Sustainable Immunization

Financing (SIF) program sponsored

a workshop on legislative and

financial strategies for immunization.

The workshop drew delegates

from ministries of health, ministries

of finance and parliaments of six

Francophone countries. Workshop

participants conducted peer reviews

of draft laws and shared strategies

for strengthening routine

immunization program financing.

FIFTH GAVI PARTNER’S FORUM Dar es Salaam, Tanzania

Sabin’s SIF program worked with

the GAVI Alliance (Global Alliance

for Vaccines and Immunisation)

to produce a series of sessions

attended by members of parliament

representing 13 African, Asian and

European countries. Nine members

of parliament spoke of their

advocacy work in SIF countries.

Sabin Executive Vice President Dr.

Ciro de Quadros, a member of

the forum’s organizing committee,

presided over two sessions.

24

Expanding in Europe

TO REALIZE BIGGER GOALS AND GREATER RESULTS

High-Level Advocacy Efforts in the United Kingdom

RT. HON. BARONESS HELENE HAYMAN GBE, a member of the Sabin Vaccine

Institute Board of Trustees, twice fueled interest in NTD elimination efforts

in the House of Lords. Following the launch of the London Declaration on

NTDs, Baroness Hayman led a parliamentary debate titled “Health: Neglected

Tropical Diseases,” where she applauded the UK Department for International

Development’s new funding commitments toward NTD programs. In July,

she pressed for further attention to NTDs in the context of broader health

programs focused on HIV/AIDS, malaria and tuberculosis.

URGING POLICYMAKERS TO TAKE ACTION ON NTDS

In June, UK Member of Parliament and Trustee of Sabin Foundation Europe

Jeremy Lefroy urged his colleagues in the House of Commons and Prime

Minister David Cameron to take action on NTDs and to continue to engage

partner governments and organizations as well as the British public in their

efforts. He was joined in his efforts by Mr. Stephen O’Brien, then the UK

Parliamentary Under-Secretary of State for International Development (2010

– 2012), and a long-time champion for malaria and NTD programs.

John Cummins Joins Board of Trustees

In January 2013, John Cummins, Group Treasurer of the Royal Bank of

Scotland, joined Sabin Foundation Europe’s Board of Trustees.

The Sabin Foundation Europe Board of Trustees

Morton P. Hyman Chairman

John Cummins Group Treasurer, Royal Bank of Scotland

Jeremy Lefroy Member of Parliament, Stafford Constituency,

House of Commons, Chairman, All-Party Parliamentary Group on

Malaria and NTDs

William D. Morrison Chairman and Member of the Board, Trinity Group

Sabin Foundation Europe (SFE), a key partner organization of the Sabin Vaccine Institute working in the United Kingdom and across Europe, significantly scaled up efforts to raise awareness and spur action to reduce the effects of vaccine-preventable and neglected tropical diseases (NTDs).

Sabin Foundation Europe

27

The Sabin Vaccine Institute 2012

Board of Trustees

Morton P. Hyman

Chairman

Founder and CEO of

MPH Enterprises, LLC

Allan L. Goldstein, Ph.D.

Professor and Emeritus Chairman

Department of Biochemistry &

Molecular Biology, The George

Washington University School

of Medicine

Rt. Hon. Baroness Helene

Hayman, GBE

Immediate Past Lord Speaker of

the House of Lords, United Kingdom

Parliament

Axel Hoos, M.D., Ph.D.

Vice President, Oncology R&D,

GlaxoSmithKline Pharmaceuticals

Kevin L. Reilly

Former Chairman of the Board,

VaxGen, Inc.

Gary Rosenthal

Partner in the Sterling Group, L.P.

Immediate Past Chairman of the Board

of Trustees, Texas Children’s Hospital

Philip K. Russell, M.D.

Past Chairman

Major General, U.S. Army Medical

Corps (Ret.)

Marc Shapiro

Non-Executive Chairman,

Chase Bank of Texas

Immediate Past Chairman of the Board

of Trustees, Baylor College of Medicine

Peter L. Thoren

Executive Vice President, Access

Industries, Inc.

Michael E. Whitham

Secretary and Treasurer

Founding partner, Whitham, Curtis,

Christofferson & Cook

Heloisa Sabin

Honorary Trustee

Senior Leadership

EXECUTIVE LEADERSHIP

Michael W. Marine,

Ambassador (Ret.)

Chief Executive Officer

Peter J. Hotez, M.D., Ph.D.

President,

Director, Sabin Vaccine Institute

and Texas Children’s Hospital Center

for Vaccine Development

Ciro de Quadros, M.D., M.P.H.

Executive Vice President,

Director, Vaccine Advocacy and

Education

Neeraj Mistry, M.D., M.P.H.

Managing Director, Global Network

for Neglected Tropical Diseases

Brian Davis, C.P.A.

Chief Operating Officer

Larry Ellingsworth, Ph.D.

Vice President,

Deputy Director, Sabin PDP

PROGRAM LEADERSHIP

Maria Elena Bottazzi, Ph.D.

Director, Product Development,

Sabin PDP

Baylor College of Medicine

Texas Children’s Hospital

Michelle K. Brooks

Director, Policy, Global Network

for Neglected Tropical Diseases

Peter Carrasco

Director, International Association

of Immunization Managers (IAIM)

Secretariat

Ana Flavia Carvalho, M.B.A., M.P.H.

Director, Special Projects, Vaccine

Advocacy and Education

David Diemert, M.D., FRCP(C)

Director, Clinical Trials, Sabin PDP

The George Washington University

Richard J. Hatzfeld

Director, Communications

Tara Hayward

Director, Resource Development

Marva Loblack, M.S., M.B.A.

Director, Regulatory Affairs and Quality

Assurance, Vaccine Development

Mike McQuestion, Ph.D., M.P.H.

Director, Sustainable Immunization

Financing

Christopher B. Nelson, Ph.D., M.P.H.

Director, Coalition against Typhoid

Secretariat

Marcia de Souza Lima, M.D., M.I.P.P.

Director, Programs and Operations,

Global Network for Neglected Tropical

Diseases

Board of Trustees and

Senior Leadership

28

The Sabin Vaccine Institute 2012

Awards and Appointments for Sabin Leadership

Sabin Executive

Vice President

Dr. Ciro de

Quadros was

awarded the

prestigious BBVA

Frontiers in Knowledge Award in the

Development Cooperation category

for leading the efforts to eliminate

polio and measles from the western

hemisphere and being one of the

most important scientists in the

eradication of smallpox around

the world.

Dr. de Quadros adds this latest

achievement to other awards

and recognition he has received

over the past three years from

prestigious organizations including

Case Western University, PAHO,

the Royal National Academy of

Medicine in Spain, the Brazilian

Ministry of Health, and Rotary

International, among many others.

Sabin President Dr. Peter Hotez

was appointed as the Baker Institute

Fellow in Disease and Poverty at the

James A. Baker III Institute for Public

Policy at Rice University. In addition,

he received the Ralph D. Feigin,

M.D. Award for Excellence from the

Immunization Partnership, and

became an elected member of the

Association of American Physicians

and a member of the Editorial Board

of the Journal of Pediatric Infectious

Diseases Society.

Dr. Hotez adds these to his recent

appointments, fellowships and

memberships over the past three

years from Baylor College of

Medicine, Texas Children’s Hospital,

The Academy of Medicine,

Engineering and Science of Texas

(TAMEST), NIH Council of Councils,

American Society of Tropical

Medicine and Hygiene and the

National Library of Medicine, among

many others.

Sabin Vaccine Institute Recognition and Appointments

In 2012, Sabin received Charity

Navigator’s highest 4-Star rating

for the fifth consecutive year, a

ranking that reflects our commitment

to transparency, accountability

and careful stewardship of funding.

Sabin was also appointed as the 51st

member of Texas Medical Center,

the world’s largest medical center.

All member institutions of the Texas

Medical Center are non-profit

organizations devoted to research,

education, patient care and the

prevention of disease and injury.

The United Nations Economic and

Social Council (ECOSOC) granted

special consultative status to

Sabin in 2012, a new opportunity to

actively engage with ECOSOC and

its subsidiary bodies, as well as with

the United Nations Secretariat

programs, funds and agencies.

Dr. F. Marc LaForce Receives 2012 Gold Medal Award

In May 2012, Sabin presented the

annual Albert B. Sabin Gold Medal

Award to Dr. F. Marc LaForce for

his integral role in developing a new

meningitis vaccine, MenAfriVac®,

which has the potential to prevent

1 million cases of disease and save

150,000 lives and up to US $300

million in medical costs over the

next decade.

The new vaccine was developed at a

cost of less than US $0.50 per dose,

and to date, more than 100 million

people in 10 countries have received

MenAfriVac®. Not a single case of

group A meningococcal meningitis

has been identified in vaccinated

individuals.

Awards and Recognition

29

The Sabin Vaccine Institute 2012 – Financial Report

Condensed Statement of ActivitiesDecember 31, 2012 and 2011

REVENUE AND SUPPORT 2012 2011

Grants, contributions and

other support received $25,393,978 $22,164,456

Future portion of grants as of year-end 41,598,275 51,411,865

Investment income 31,516 24,717

TOTAL 67,023,769 73,601,038

EXPENSES

Program services 19,401,006 22,749,027

General, administrative and fundraising 2,111,781 2,217,039

TOTAL 21,512,787 24,966,066

EXCESS OF REVENUES, COMMITMENTS

AND SUPPORT OVER EXPENSE $45,510,982 $48,634,972

2012 FUNCTIONAL EXPENSE ALLOCATION:

90% 10%

Sabin's Board of Trustees and executive leadership are fully committed to responsible and effective stewardship of donor funding. For the fifth consecutive year, Sabin received Charity Navigator's highest rating for consistently executing our mission in a fiscally responsible way.

Program Services General, Administrative and Fundraising

30

The Sabin Vaccine Institute 2012 – Financial Report

Condensed Statement of Financial PositionDecember 31, 2012 and 2011

ASSETS 2012 2011

Cash, equivalents and other current assets $12,735,970 $12,893,780

Investments 14,493,641 12,056,655

Other assets 72,324 85,095

TOTAL ASSETS 27,301,935 25,035,530

LIABILITIES AND NET ASSETS

Accounts payable and accrued expenses 2,503,493 3,956,238

Other liabilities 468,065 661,622

TOTAL LIABILITIES 2,971,558 4,617,860

Unrestricted net assets 2,138,685 1,982,925

Temporarily restricted net assets 22,191,692 18,434,745

TOTAL NET ASSETS 24,330,377 20,417,670

TOTAL LIABILITIES AND NET ASSETS $27,301,935 $25,035,530

2012 PROGRAM EXPENSE ALLOCATION:

36% 36% 28%

The financial statements presented have been summarized from Sabin's audited financial statements.

Sabin's full audit report, completed by Rogers & Co, LLP, is available at www.sabin.org.

Vaccine Development Vaccine Advocacy and Education

Global Network

31

The Sabin Vaccine Insititute 2012

To Our Partners, Collaborators and Contributors from around the World

A Abbott LaboratoriesAerasAfrican Programme for Onchocerciasis ControlAfrican Union Mission to the United States Aga Khan University [Pakistan]Agence de Médecine Préventive [France]American Public Health AssociationASEAN Foundation Asian Development Bank Association for Immunization Managers

BBaylor College of Medicine Bharat Biotech [India]Bill & Melinda Gates FoundationbioMérieuxBIRMEX [Mexico]Blavatnik Family FoundationMs. Emily BluntBrazilian Society of Immunizations [Brazil]

CCatholic Medical Mission BoardCBM InternationalCenter for Research and Advanced Studies of the National

Polytechnic Institute [Mexico]Center for Strategic and International StudiesCenter for Vaccine Development at the University of MarylandMs. Yvonne Chaka ChakaChiapas State Government [Mexico]Children’s National Medical Center Ms. Priyanka ChopraCommunes et Villes Unies du Cameroun [Cameroon]Covington & BurlingCreative Artists Agency FoundationCrucell [Switzerland]Mr. Richard Curtis

DDepartment for International Development [United Kingdom]DiaSorin [Italy]Drugs for Neglected Diseases InitiativeDubai Cares [United Arab Emirates]

EEisai Co., Ltd. [Japan]Embassy of Nigeria [Nigeria]Embassy of South Africa [South Africa]EMI Music

FMr. Russell B. FaucettMr. Tom FeltonFEMSA Foundation [Mexico]Finlay Institute [Cuba]Fondation Mérieux [France]Fraunhofer Center for Molecular BiotechnologyFrontier BioSciences, Inc. [China]Fundação Oswaldo Cruz [Brazil]Fundación Cinépolis [Mexico]Fundación Mundo Sano [Argentina]

GGAVI AllianceGlaxoSmithKlineGlobal Health Partnership InitiativeGlobal Health Technologies CoalitionGovernment of the Municipality of Recife [Brazil]Governments and Parliaments of Bhutan, Cambodia, Cameroon,

Democratic Republic of Congo, Republic of Congo, Ethiopia, Kenya, Liberia, Madagascar, Mali, Mongolia, Nepal, Nigeria, Senegal, Sierra Leone, Sri Lanka, Uganda, Vietnam

HHelen Keller InternationalHoffmann-La Roche Inc.Mr. Tom HollanderHospital de Niños Dr. Ricardo Gutierrez [Argentina]Hospital de Niños Roberto del Río [Chile]Hudson Institute Mr. and Mrs. Morton and Chris Hyman

I/Jicddr,b [Bangladesh]IMA World HealthImmune Design CorporationInstitut PasteurInstituto Balseiro [Argentina]Instituto Butantan [Brazil]Instituto Carlos Slim de la Salud [Mexico]Instituto Conmemorativo Gorgas de Estudios de la Salud [Panama]Inter-American Development BankInternational Trachoma Initiative

International Vaccine Institute [Republic of Korea]Ms. Aigerim Jakisheva James Cook University [Australia]

LLions Club of Nepal [Nepal]Liverpool School of Tropical Medicine [United Kingdom]London School of Hygiene and Tropical Medicine [United Kingdom]

M/NMarch of Dimes FoundationMerck & Co., Inc.Dr. Gary K. MichelsonMinisterio de Salud de la Nación [Argentina]Ministerio de Salud República de Panamá [Panama]Ministry of Foreign Affairs, Government of the Netherlands [The Netherlands]Ministry of Health of Brazil [Brazil]Ministry of Health of Thailand [Thailand]New York Blood CenterNovartis Vaccines Institute for Global Health [Italy]

OOxford University Clinical Research Unit at the Hospital for Tropical Diseases [Vietnam]Oxford Vaccine Group [United Kingdom]

P/QPan American Health Organization PATHPfizer Inc. Planty & Associates LLCQueensland Institute of Medical Research [Australia]

RMr. Eddie RedmayneRotary Clubs [Nepal, Cameroon]

SSanofi Pasteur SASanofi-Aventis U.S. LLC.Santa Casa de São Paulo [Brazil]Mrs. Alicia Zarou Scanlon Schistosomiasis Control Initiative Mr. and Mrs. Marvin and Donna SchwartzSecretaría de Salud [Mexico]

Thank you

32

The Sabin Vaccine Insititute 2012

Serum Institute of India Ltd. [India]SevenlyShantha Biotech [India]SouthWest Electronic Energy Medical Research Institute

TTexas Children’s Hospital The Earth Institute at Columbia UniversityThe END FundThe Infectious Disease Research InstituteThe George Washington University Department of Microbiology, Immunology and Tropical Medicine The Leprosy Mission Canada [Canada]The Social Investment Consultancy The Task Force for Global Health

U/VUganda Local Governments Association [Uganda]UNICEFUniversidad Autónoma de la Yucatán [Mexico]Universidad Nacional de Colombia, Departamento de Salud Publica [Colombia]Universidade Federal da Bahia, Faculdade de Medicina [Brazil]University of Kansas University of Notre Dame, Haiti Program

University of Otago, New Zealand [New Zealand]University of PittsburghUniversity of Texas Medical Branch U.S. Agency for International DevelopmentU.S. Centers for Disease Control and PreventionU.S. National Institutes of Health, Fogarty International CenterU.S. National Institutes of Health, National Institute of Allergy and

Infectious Diseasesvfa [Germany]

WWalter Reed Army Institute of ResearchWebb Family Foundation Wellcome Trust [United Kingdom]Wellcome Trust Sanger Institute [United Kingdom]World Health Organization World Health Organization Initiative for Vaccine Research (IVR)World Health Organization, Regional Office for Africa World Health Organization, Regional Office for EuropeWorld Health Organization, Regional Office for South-East Asia World Health Organization, Western Pacific RegionWunderman [United Kingdom]

CreditsPhotography / Cover photo: Esther Havens / pg. 2-3 Esther Havens / pg. 4 Olivier Asselin / pg. 5 Olivier Asselin / pg. 6 Jessica Stuart / pg. 7 Olivier Asselin / pg. 8 Olivier Asselin / pg. 9 Evan Wilder (top), Olivier Asselin (bottom) / pg. 10 Olivier Asselin / pg. 11 Olivier Asselin / pg. 12 National School of Tropical Medicine / pg. 13 Brett Coomer (top), Getty Images/Ingram Publishing (middle), CDC Public Health Image Library (bottom) / pg. 14 CDC Public Health Image Library (all) / pg. 15 Olivier Asselin / pg. 16 Richard Hatzfeld / pg. 17 Evan Wilder / pg. 18 Olivier Asselin / pg. 19. Esther Havens / pg. 20 Esther Havens / pg. 21 CDC Public Health Image Library (left), Gustavo Alric (middle), Esther Havens (right) / pg. 22 Svenja Knoedler (left top), Oliver Asselin (left bottom) Quo - Bangkok (middle), Anna Grove (right) / pg. 23 Deborah Hong (top right), Sayam Eiampichairit (top middle) / pg. 24 National School of Tropical Medicine (left), Olivier Asselin (right) / pg. 25 Olivier Asselin / pg. 26 Olivier Asselin / pg. 29 BBVA Foundation(left), The Immunization Partnership (middle), Evan Wilder (right) / pg. 33 Esther Havens Design / BÜRO SVENJA

Carrying a Legacy ForwardThe Sabin Vaccine Institute was founded in

1993 in honor of Dr. Albert B. Sabin, a scientist,

humanitarian and hero. His success in

developing the oral polio vaccine has saved

countless lives and eliminated millions of cases

of illness and disability. Over the last 25 years,

polio cases have been reduced by 99 percent;

the economic benefit of eradicating polio is

estimated to be US $40-50 billion.

Sabin Vaccine Institute

2000 Pennsylvania Avenue, NW

Suite 7100

Washington, D.C. 20006

Phone : +1 (202) 842-5025

Web : www.sabin.org

: www.facebook.com/sabinvaccine

: @sabinvaccinePrinted on recycled paper using

vegetable-based inks and 100% wind power.

Sabin Vaccine Institute 2012 Annual Report

Documents